Item 4. CONTROLS AND PROCEDURES
3K characters. Original on sec.gov ·
Item 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of the Chief Executive
Officer and Chief Financial Officer (the Certifying Officers),
evaluated the effectiveness of the Company's disclosure controls
and procedures (as defined in Rules 13a-15(e) or 15d-15(e)
promulgated under the Securities Exchange Act of 1934, as
amended) on September 30, 2026. Based on that evaluation, the
Certifying Officers concluded the Company's disclosure controls
and procedures were effective as of September 30, 2026.
Changes in Internal Control Over Financial Reporting
There was no change to our internal control over financial
reporting during the nine months 2026 that materially affected, or
is reasonably likely to materially affect, our internal control over
financial reporting.
PART II – OTHER INFORMATION
| Item 1A. RISK FACTORS |
We are not aware of any material changes to the risk factors
included in Item 1A. "Risk Factors" in our Annual Report on Form
10-K for 2025 and Part II, Item 1A. "Risk Factors" in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2026.
| Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
In the three months 2026 we did not issue shares of our common
stock as performance incentive awards to employees. When
issued, these shares are not registered under the Securities Act
of 1933 based on the conclusion that the awards would not be
events of sale within the meaning of Section 2(a)(3) of the Act.
In March 2015 we announced that our Board of Directors had
authorized us to purchase up to $2,000 of our common stock. In
October 2026 our Board of Directors approved an increase of
$3,000 to our existing share repurchase program, bringing the
total share repurchase authorization to $3,033. The manner,
timing and amount of repurchases are determined by
management based on an evaluation of market conditions, stock
price, and other factors and are subject to regulatory
considerations. Purchases may be made from time to time in the
open market, in privately negotiated transactions, accelerated
share repurchase programs or otherwise.
In 2026 we repurchased 3 million shares of our common stock at
a cost of $1,000 under our authorized share repurchase program.
The total dollar value of our shares of common stock that could
be acquired under our authorized repurchase program was $33
as of September 30, 2026.
| 2026 Period | Total Number of Shares Purchased (in millions) | Average Price Paid Per Share | Purchased as Part of Publicly Announced Plans (in millions) | Approximate Dollar Value of Shares that may yet be Purchased Under the Plans | |||
| July | — | $— | — | $1,033 | |||
| August | 2.8 | 335.17 | 2.8 | 83 | |||
| September | 0.2 | 321.61 | 0.2 | 33 | |||
| Total | 3 | $334.46 | 3 |
Previous: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK · Next: Item 5. OTHER INFORMATION